Clinical trial registry changes: June 2026

Among the trials TrialRedline tracks, 70 changed their ClinicalTrials.gov record in June 2026: 5 status changes to terminated, withdrawn or suspended, 12 primary outcome text edits, 20 completion dates moved later, 3 completion dates moved earlier, 24 enrollment changes, 28 other status changes. Each entry shows the previous and updated value and links to the registry's own version comparison.

70Trials with a recorded change
70Registry updates
58Sponsors

Trials terminated, withdrawn or suspended

5 in June 2026. Recruitment status changed to Terminated, Withdrawn or Suspended. Terminated first, then newest.

Primary outcome text edits

12 in June 2026. The text of the main study measures changed. Edits to capitalization, punctuation or spacing alone are left out. Newest first.

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Evaluation of efficacy of AL001 as measured by the CDR® plus NACC FTLD-SB. After: Measure: Part 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo as Measured by the CDR® Plus NACC FTLD-SB in Symptomatic Patients Measure: Part 1 Double Blind (Co-Primary US Endpoint) - Evaluation of the Treatment Effect of AL001 Compared With Placebo as Measured by Pharmacodynamic and Disease Pathology Biomarkers in Symptomatic Patients Measure: Part 2 OLE - To Assess the Long-term Safety and Tolerability of AL001 in Participants Who Have Completed Part 1 of the Study.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of Patients Who Achieve at Least a 10-point Improvement From Baseline in KOOS-Child Pain and Function (Sports and Recreational Activities) Scores. After: Measure: Proportion of Participants Who Achieve ≥ 10-point Improvement From Baseline in KOOS-Child Pain and Function (Sports and Recreational Activities) Subscale Scores.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To assess the safety and tolerability of study drug treatment regimens. After: Measure: Percentage of participants who experienced an adverse event.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To characterize the effect of bexotegrast versus placebo on the change in forced vital capacity (FVC) in participants with idiopathic pulmonary fibrosis (IPF). After: Measure: Change From Baseline in Forced Vital Capacity at Week 52.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of Participants With a Sternal Wound Infection Event. After: Measure: Number of Participants With a Sternal Wound Infection Event.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Progression-Free Survival (PFS). After: Measure: Percent of Patients who Experience Dose Limiting Toxicity (DLT) (Part 1) Measure: Number of Patients with 1 or More Adverse Events (AEs) Leading to Study Drug Discontinuations or Dose Modifications (Part 1) Measure: Progression-Free Survival (PFS) (Part 2).

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Complete wound closure of the index ulcer Measure: Safety (adverse events [type, frequency, and severity of AEs, and relationship of AEs to study drug], laboratory abnormalities, and hospitalizations. After: Measure: Percentage of Subjects With Complete Wound Closure of the Index Ulcer Within 3 Months.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Safety: Treatment-emergent adverse events (TEAEs) Measure: Change in disease activity biomarkers. After: Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Measure: Maximum Change From Baseline in Hemoglobin Levels Measure: Change From Baseline in Lactate Dehydrogenase Levels at Day 71 Measure: Change From Baseline in Percentage of Reticulocytes/Total Cells Count at Day 71 Measure: Change From Baseline in Haptoglobin Levels at Day 71 Measure: Change From Baseline in Total Bilirubin Levels at Day 71 Measure: Change From Baseline in Indirect Bilirubin Levels at Day 71.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Phase 2: Assessment of Novel Patient Reported Outcome Instrument Psychometric Properties Measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole Measure: Phase 2: Percentage of Participants Achieving Clinical Response Measure: Phase 3: Percentage of Participants Achieving Clinical Response. After: Measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole Measure: Phase 2: Percentage of Participants Achieving Clinical Response Measure: Phase 3: Percentage of Participants Achieving Clinical Response.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Progression free survival. After: Measure: Part A: Safety and Tolerability - Adverse Events Measure: Part B: Progression free survival (PFS).

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To assess the anti-infective efficacy of D-PLEX over a period of 30 days post operation, by preventing surgical site infection (SSI), defined as superficial and deep infection, in the target incision(s), compared to the SoC treated control. Measure: Safety of D-PLEX in Prevention of Post Abdominal Surgery Measure: Safety of D-PLEX in Prevention of Post Abdominal Surgery Incisional. After: Measure: Infection Rate as Measured by the Proportion of Subjects With an Surgical Site Infection (SSI) Event in the Population of Subjects With Target Incision Length >20 cm.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Placebo-adjusted change from baseline in automated office blood pressure (AOBP) systolic blood pressure (SBP) at Week 4 Measure: Incidence and severity of adverse events (AEs). After: Measure: Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) Systolic Blood Pressure (SBP) at Week 4.

Check registry source

Completion dates moved later

20 in June 2026. Primary completion date moved later while its type (estimated or actual) stayed the same. Largest move first.

Completion dates moved earlier

3 in June 2026. Primary completion date moved earlier while its type stayed the same. Largest move first.

Enrollment changes

24 in June 2026. The participant count changed. Planned and actual counts are shown as recorded. Newest first.

Other recruitment status changes

28 in June 2026. Any other change of recruitment status, such as recruiting to completed. Newest first.

Showing 25 of 28. Browse all tracked trials to open the rest.

Cite this report

TrialRedline, “Clinical trial registry changes: June 2026”. https://trialredline.com/reports/2026-06

Based on public ClinicalTrials.gov record history. How we collect and check the data